MedTrace Logo

Postpartum Hypertension Study

NCT05139238 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2026-05-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess which blood pressure medication (intravenous labetalol or oral nifedipine) works better in treating severely elevated blood pressure in women who have just delivered a baby.

Conditions

  • Postpartum Pregnancy-Induced Hypertension
  • Postpartum Preeclampsia
  • Pregnancy-Induced Hypertension in Postpartum
  • Hypertensive Emergency

Interventions

DRUG

Labetalol

Intravenous labetalol, a short acting ant-hypertensive

DRUG

Nifedipine

Oral nifedipine, a short acting ant-hypertensive

Sponsors & Collaborators

Principal Investigators

  • Whitney A. Booker, MD · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-04
Primary Completion
2025-08-21
Completion
2025-08-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05139238 on ClinicalTrials.gov